Acarix
Acarix is a Swedish medical technology company built around the CADScor System, a noninvasive diagnostic platform used to assess the likelihood of coronary artery disease. The company’s business combines device sales, disposable patch sales, and market development for use in clinical settings, with activity centered in Europe and the United States.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueNoninvasive diagnostic system used to assess coronary artery disease risk.
Single-use patches consumed with each CADScor test.
Market access, training, and related support for adoption of the system.
Customers
Acarix sells primarily to healthcare providers that evaluate patients with suspected coronary artery disease and need a noninvasive triage tool. Its customer base also includes hospitals, clinics, and channel partners that help place the system into clinical workflows, especially in markets where reimbursement and regulatory acceptance matter.
Buy the CADScor System to support coronary artery disease assessment in clinical workflows
Use the system for noninvasive patient triage and repeat testing
Help place the product in new markets and support adoption
Strategy
Acarix’s strategy centers on expanding acceptance of the CADScor System, especially in the U.S. market, while securing the financing needed to support commercialization. The company also emphasizes partnerships, regulatory progress, and broader clinical adoption to move the product into routine use.
The U.S. market offers the largest near-term opportunity for system placements and patch sales
Clinical adoption depends on approval, reimbursement, and inclusion in care pathways
Commercial rollout and product development require ongoing capital support
Geography
Acarix’s disclosed sales activity spans Europe and the United States, with the U.S. highlighted as an important growth market in recent reporting. The company also has historical sales in Germany, Sweden, Austria, and other European markets, which makes reimbursement, regulatory approvals, and local clinical adoption important to the business model.
Risks
Acarix faces commercialization risk because adoption of a new medical device can take time and may not translate into sufficient revenue. The company is also exposed to financing, regulatory, competitive, and supply-chain risks typical of early-stage medtech businesses, with market acceptance and reimbursement being especially important.
- Financing and going-concern riskImpact: CriticalLikelihood: High
Commercialization and development require external capital until the business scales
Exposure: Company-wide
- Market acceptance of CADScor SystemImpact: HighLikelihood: Medium
Revenue depends on clinicians adopting a new diagnostic workflow and trusting the product
Exposure: Core product commercialization
- Regulatory and reimbursement delaysImpact: HighLikelihood: Medium
Market launches may require approvals and payer acceptance before sales can scale
Exposure: Target markets
- Competition and obsolescenceImpact: MediumLikelihood: Medium
Alternative diagnostic tools could limit adoption if they are cheaper or more established
Exposure: CAD diagnostics market
- Supply-chain and trade disruptionImpact: MediumLikelihood: Medium
Imported components and cross-border operations can be affected by tariffs or logistics issues
Exposure: Hardware and consumables
Accounting
Judgemental itemsSales are recognized when control transfers, so shipment timing affects quarterly revenue
Impact: Point-in-time recognition for goods
Premises and car leases create right-of-use assets and liabilities
Impact: Affects balance sheet leverage and operating expense presentation
Financial statements depend on expected capital raises and runway
Impact: Can materially affect classification and disclosure
Capitalized or expensed development and any impairment tests can change reported results
Impact: Important for a small R&D-driven medtech company
Similar listed companies
Publicly listed companies with a comparable business focus.
CareDx, Inc.
CDNA · Services-Medical Laboratories
LadRx Corp
Biological Products, (No Diagnostic Substances)
LadRx Corp is a Delaware-based biopharmaceutical research company focused on oncology drug discovery and clinical development.
Aditxt, Inc.
ADTX · Pharmaceutical Preparations
Akari Therapeutics Plc
AKTX · Pharmaceutical Preparations
Akari Therapeutics Plc is a clinical-stage biotechnology company that has shifted its focus toward oncology, specifically next-generation antibody-drug…
Asker Healthcare Group
ASKER · Health Care
Asker Healthcare Group is a prominent European provider of medical products and solutions, focusing on improving patient outcomes and reducing healthcare costs.
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Last updated: 24/09/2026